ReviewJHEP reports : innovation in hepatology2025
Regulatory T cell therapy in autoimmune liver disease and transplantation.
Review in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Regulation of follicular helper T cell subset differentiation in health and disease.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Regulatory T cells from concept to clinic: The 2025 Nobel Prize and its implications for immune-mediated diseases and cancer.Biomedical journal · 2026Review
- Regulatory T-cells in autoimmune hepatitis: An historical perspective with hints to the future.JHEP reports : innovation in hepatology · 2026Article
- Regulatory T-cell remodeling across the HBV infection-cirrhosis continuum.Frontiers in immunology · 2026Review
- Regulatory T cells in intracerebral hemorrhage: mechanisms of immunomodulation and therapeutic potential.Frontiers in immunology · 2026Review
- Crosstalk along the gut-liver axis modulates glutathione and cadmium-induced hepatotoxicity.Frontiers in immunology · 2026Review
- Regulatory T cell therapy in solid organ transplantation: mechanisms, translational progress, and remaining barriers.Frontiers in immunology · 2026Review
- Method for generation and ex vivo expansion of genetically edited mouse Tregs.Journal of leukocyte biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, we explore the application of regulatory T cells (Tregs) as cellular therapies in the setting of autoimmune liver diseases and liver transplantation. At present, there are limited treatment options for end-stage liver disease, which in many cases requires transplantation. Following liver transplantation, immunosuppressive drugs are administered, often throughout the course of the patient's life, to prevent organ rejection. When used for a prolonged period, immunosuppressive drugs can have detrimental effects on the patient's health and quality of life. Tregs are an attractive target for cellular therapy in this context because of their innate ability to control inflammatory immune responses. In this review, we cover the different generations of Treg-based therapies, their potential roles in the treatment of autoimmune liver diseases and transplantation, and the future outlook for Tregs as cellular therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.